Immune Thrombocytopenic Purpura
43
2
2
29
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.3%
1 terminated out of 43 trials
96.7%
+10.2% vs benchmark
26%
11 trials in Phase 3/4
31%
9 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (43)
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura
Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq
Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
A Study of PN20 in Healthy Adult Volunteers
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital
" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.
Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP